Details of the Drug Combination

General Information of Drug Combination (ID: DC9FRM2)

Drug Combination Name

GSK2194069 Testolactone

Indication

Disease Entry	Status	REF
Chronic myelogenous leukemia	Investigative	[1]

Component Drugs

GSK2194069 DMZ2TD9

Testolactone DMVY4GN

Small molecular drug

2D MOL

3D MOL is unavailable

3D MOL

High-throughput Screening Result

Testing Cell Line: KBM-7

Zero Interaction Potency (ZIP) Score: 15.56

Bliss Independence Score: 15.56

Loewe Additivity Score: 28.29

LHighest Single Agent (HSA) Score: 28.31

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of GSK2194069

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[2]

GSK2194069 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Fatty acid synthase (FASN)	TT7AOUD	FAS_HUMAN	Inhibitor	[2]
------------------------------------------------------------------------------------

Indication(s) of Testolactone

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[3]

Testolactone Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Aromatase (CYP19A1)	TTSZLWK	CP19A_HUMAN	Inhibitor	[4]
------------------------------------------------------------------------------------

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2	A human fatty acid synthase inhibitor binds beta-ketoacyl reductase in the keto-substrate site. Nat Chem Biol. 2014 Sep;10(9):774-9.
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7303).
4	Aromatase inhibitors for male infertility. J Urol. 2002 Feb;167(2 Pt 1):624-9.